Skip to content

Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis

By API User

Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conventional treatment options or tumor necrosis factor (TNF) antagonists, found nearly half (47.3%) of randomized patients achieved primary endpoint of clinical remission at 54 weeks Vedolizumab’s safety profile was generally consistent … Continued

Ecopha Group Inc. Recognised as One of the Most Innovative Companies to Watch in 2026 by The CEO Vision.

By API User

Key Facts: • Recognised by CEO Vision as one of the Most Innovative Companies to Watch in 2026• Incorporated in Delaware, USA in 2024 as part of global expansion strategy• Preparing for a future Nasdaq listing• Producer of EcoPHA, a next-generation PHA bioplastic derived from non-food Pongamia oil• 100 per cent bio-based, fully biodegradable, home … Continued

YolTech Therapeutics Announces Positive Interim Data on YOLT-202 for the Treatment of Alpha-1 Antitrypsin Deficiency

By API User

Single dose of YOLT-202 led to rapid, robust and dose-dependent increases in AAT levels to normal range Single dose of YOLT-202 was well tolerated with a favorable safety profile SHANGHAI–BUSINESS WIRE– YolTech Therapeutics, a late clinical-stage biotechnology company developing in vivo gene editing therapies, today announced positive interim data from an investigator-initiated trial (IIT) of … Continued

On this weekend – Memory Walk & Jog Canberra!

By API User

The 2026 Canberra Memory Walk & Jog is fast approaching, with the much-anticipated event taking place this weekend on Sunday 22 February at Stage 88, Parkes.   With the big day kicking off at 7:30am, we welcome everyone in the Canberra community to join their fellow participants as they walk, jog or run for better … Continued

Get active for your brain health and beat dementia in Illawarra!

By API User

The 2026 Illawarra Memory Walk & Jog is just weeks away, with the event taking place on Sunday 22 March at Lang Park, Illawarra.    As Dementia Australia’s largest annual fundraising initiative, Memory Walk & Jog brings communities together to get active, get connected and support Australians living with dementia, their families and carers.   … Continued

Number of future GPs training with RACGP almost triples in NT

By API User

Patients in the Northern Territory will soon find it easier than ever to see a GP, with a record number of future specialist GPs commencing specialist training in the Commonwealth-funded Australian General Practice Training (AGPT) Program with the Royal Australian College of GPs (RACGP). In 2026, 31 future GPs have commenced training in the Northern … Continued

New FAP-Index could transform early detection of severe liver disease

By API User

Researchers from the Centenary Institute have developed a new diagnostic tool, the FAP-Index, that could significantly improve how doctors identify people at risk of serious liver damage caused by metabolic fatty liver disease. The condition affects around one in three Australians with cases projected to increase by 25% to over 7 million by 2030.   … Continued

Record growth in future GPs a boost for primary care in Tasmania

By API User

Patients in Tasmania will soon find it easier than ever to see a GP, with a growing cohort of future specialist GPs commencing training in the Commonwealth-funded Australian General Practice Training (AGPT) Program with the Royal Australian College of GPs (RACGP). In 2026, 56 future GPs have commenced training in Tasmania, a 19% increase on … Continued

RACGP welcomes free RSV vaccinations for older Western Australians

By API User

The Royal Australian College of GPs (RACGP) has welcomed the Western Australian Government’s announcement that older Western Australians living in residential aged care will receive free RSV immunisation through a new $2.6 million state-funded program. For the first time, the Arexvy RSV vaccine, which normally costs around $300 privately, will be made available at no … Continued

Improving laboratory management and patient outcomes – Q-Sera announces first product launch of its RAPClot(TM) rapid serum blood collection tube technology in Japan

By API User

Melbourne, Australia – February 19, 2026 – Q-Sera Pty Ltd, an Australian venture-backed company, today announced that leading Japanese medical device company, Terumo Corporation has launched VenoJect II RAPClotTM evacuated blood collection tubes in the Japanese market. These next-generation tubes incorporate Q-Sera’s patent protected technology and will improve laboratory management and patient outcomes.       … Continued